Silexion Therapeutics (SLXN) announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer models. This ...
The Company anticipates sharing initial results from the study in March 2025. These results will inform Silexion's development strategy for SIL-204.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Silexion Therapeutics Corp. (SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today ...
After hours: 7:59:51 p.m. EST Loading Chart for SLXN ...
CURRENC Group Inc. operates fintech platform for e-wallets, financial institutions, and merchants worldwide. The company’s services include merchant payment, global remittance, global bill ...
BSLK Bolt Projects Holdings, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback